Exopharm - Extending Health Span

Exopharm’s mission is to be a leader in the field of clinical human therapeutics using exosomes as regenerative medicine products.

Exopharm is an Australian regenerative medicine biopharmaceutical company that is seeking to develop and commercialise exosomes as therapeutic agents – initially a product called Plexaris™ and later as a product called Exomeres™.

As key messengers within the human body, exosomes are able to exert powerful effects on the actions and behaviours of cells that they associate with. Recent research shows that exosomes are potent, broad acting, have effects that are both long-term and short-term and play key roles in many important mechanisms involved in ageing, diseases and degeneration/regeneration.

Despite the logic and promise of administering exosomes as a cell-free treatment, the therapeutic exosome market is currently held back by one key technological challenge: an efficient proprietary exosome extraction and purification process technology that would enable the manufacture of a proprietary exosome product at clinical and then pharmaceutical grade and scale.

Exopharm's LEAP Technology provides a key step in the downstream manufacturing process to isolate and purify exosomes from adult stem cells and other sources. The LEAP Manufacturing Process has been developed to address the existing limitations in exosome purification processes and gives Exopharm the opportunity to unlock the potential of exosomes as a new generation therapeutic product for regenerative medicine.

About Exopharm and the LEAP technology

Watch the below video explanation of Exopharm, the LEAP Technology and the Plexaris and Exomere products.

Footer

Resources

ASX Announcements
Financial Reporting
Board of Directors

Information

Contact
Privacy, Terms and Conditions
Corporate Directory
Join Our Mailing List

Search this website

Web Design by Mallee Blue Media